MAPT and Alzheimer disease: To test whether these peptides could be used for epitope targeting, we selected short peptide sequences from amyloid-β and Tau proteins, both of which have been used in clinical-stage conjugate vaccines for Alzheimer’s disease.16,21 P15 peptides synthesized with N- or C-terminal epitopes showed the same general distribution in particle size, although N-terminal additions were slightly larger.